Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 15 December 2025 - 24 December 2025

AbbVie Stock (ABBV) After Hours on Dec. 24, 2025: What Happened Today and What to Know Before the Next Market Open

AbbVie Stock (ABBV) After Hours on Dec. 24, 2025: What Happened Today and What to Know Before the Next Market Open

AbbVie Inc. (NYSE: ABBV) finished the shortened Christmas Eve session higher, and the stock has been essentially flat in after-hours trading—a setup that puts the focus less on “breaking” headlines and more on positioning, policy risk, and the company’s 2026 catalyst calendar. ABBV ended the day at $229.89 (+0.48%) and was $229.90 in extended trading around 5:00 p.m. ET. StockAnalysis AbbVie stock price after the bell today (Dec. 24, 2025) U.S. equities traded on a holiday-shortened schedule today. The NYSE’s calendar shows an early close at 1:00 p.m. ET on Wednesday, Dec. 24, 2025, with Christmas Day (Dec. 25) listed
24 December 2025
····
AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie Inc. (NYSE: ABBV) finished Tuesday’s session (December 23, 2025) modestly higher and then held steady in after-hours trading—an important detail heading into a holiday-shortened next session where liquidity can be thin and headlines can move prices faster than usual. Below is what investors are watching tonight: the after-hours tape, the policy backdrop around U.S. drug pricing, and AbbVie-specific developments ranging from pipeline strategy beyond Botox to a late-day legal update tied to Orilissa. AbbVie stock after hours: the numbers investors are tracking AbbVie shares closed Tuesday at $228.79, up roughly 0.4% on the day, and traded slightly higher shortly
24 December 2025
····
AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie Inc. (NYSE: ABBV) stock traded mostly steady to slightly higher on Tuesday, Dec. 23, 2025, as investors balanced a holiday-shortened trading week with a fresh burst of company-specific pipeline headlines and ongoing debate about U.S. drug-pricing policy. As of Tuesday afternoon, ABBV changed hands around $228.62, up about 0.31% on the day, after trading in a $227.88–$230.77 range. What stands out on Dec. 23 is less about a single blockbuster “breaking” announcement and more about a cluster of signals—pipeline ambition in aesthetics and therapeutics, late-stage movement in eye care, and the ever-present question for long-term holders: how durable is
23 December 2025
·····
AbbVie Stock After Hours (ABBV): Shares Dip After the Bell on Dec. 22, 2025 — Key News, Forecasts, and What to Watch Before Tuesday’s Open

AbbVie Stock After Hours (ABBV): Shares Dip After the Bell on Dec. 22, 2025 — Key News, Forecasts, and What to Watch Before Tuesday’s Open

AbbVie Inc. (NYSE: ABBV) ended Monday’s regular session (December 22, 2025) modestly higher, then slipped in early after-hours trading as investors headed into a holiday-shortened week with Washington drug-pricing headlines still hanging over large-cap pharma. ABBV closed up about 0.48% at $227.91 in Monday’s session. MarketWatchIn extended trading, ABBV was quoted around $226.05 at about 5:15 p.m. ET, down roughly 0.82% from the regular-session close. Yahoo Finance After-hours moves can be noisy—particularly in late December when liquidity thins—so the more important question for Tuesday (December 23) is what could actually change the narrative before the opening bell. AbbVie stock price
23 December 2025
·····
AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Inc. (NYSE: ABBV) is trading near recent highs on Monday, December 22, 2025, as investors weigh a powerful mix of policy risk, shareholder returns, and pipeline momentum heading into 2026. The big near-term variable isn’t a clinical readout—it’s Washington. After the White House unveiled sweeping “most-favored-nation” (MFN) drug-pricing agreements with nine large manufacturers on December 19, AbbVie remains one of the last major drugmakers still outside the deal. The White House+1 At the same time, AbbVie’s core fundamentals continue to be anchored by its immunology franchise—Skyrizi and Rinvoq—alongside a rising dividend profile and a pipeline that includes late-stage programs
22 December 2025
·····
AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Inc. (NYSE: ABBV) heads into the Monday, December 22, 2025 U.S. market open with a familiar bull case—Skyrizi and Rinvoq continuing to replace lost Humira revenue—and a less familiar overhang: Washington’s accelerating push to reframe U.S. drug pricing through “most‑favored‑nation” style commitments and new direct-to-consumer programs. Below is what investors and traders should keep on their radar before the opening bell, using the most recent available company updates, analyst forecasts, and late‑breaking policy developments. 1) Where AbbVie stock stands heading into Monday AbbVie last closed at $226.82 (Friday, Dec. 19), up about 1.8% on the day. StockAnalysis+1 One detail
22 December 2025
·····
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. (NYSE: ABBV) heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing forces: strong underlying fundamentals (Skyrizi/Rinvoq momentum, updated 2025 outlook, and a higher dividend) and a renewed policy overhang as Washington accelerates its latest push to align U.S. drug prices with lower international benchmarks. Below is a practical, week-ahead roadmap of the latest news, forecasts, and market analysis investors are weighing right now. ABBV stock snapshot entering the week AbbVie shares
21 December 2025
·····
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

December 21, 2025 — AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 near multi‑month highs, but the weekend news cycle (starting December 20, 2025) has put a familiar theme back in the spotlight: U.S. drug pricing policy. At the same time, Wall Street’s newest notes show a market still split between strong fundamentals (Skyrizi/Rinvoq momentum and a dividend raise) and policy/pipeline debates that could shape sentiment into 2026. ABBV last traded around $226.82 after Friday’s session, up about 1.8% on the day, and sitting within striking distance of its 52‑week high. MarketWatch Where AbbVie stock stands as
21 December 2025
·····
AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

December 20, 2025 — AbbVie Inc. (NYSE: ABBV) is closing out the week in the spotlight as U.S. drug-pricing policy headlines collide with a still-strong “post-Humira” growth narrative built around Skyrizi and Rinvoq. The stock finished the last regular session (Friday, Dec. 19) at $226.82, up 1.80%, while trading volume surged well above its recent average — a sign that investors were repositioning into large-cap pharma after a rapid sequence of Washington announcements. MarketWatch Below is a full roundup of what’s driving AbbVie stock right now (as of 20.12.2025), what analysts are forecasting, and which catalysts could matter most heading
20 December 2025
·····
AbbVie Stock (ABBV) After Hours Today: What’s Moving the Shares on Dec. 18, 2025 — and What to Watch Before the Market Opens Friday

AbbVie Stock (ABBV) After Hours Today: What’s Moving the Shares on Dec. 18, 2025 — and What to Watch Before the Market Opens Friday

AbbVie Inc. (NYSE: ABBV) ended Thursday’s session modestly lower, then ticked higher in after-hours trading as investors digested a fresh mix of U.S. drug-pricing policy headlines and broader pharma news that could shape sentiment into Friday’s open. AbbVie stock price after the bell (Dec. 18, 2025) AbbVie shares closed at $222.82, down 0.66% on the day. The stock traded between $222.79 and $226.26, with about 4.76 million shares changing hands. StockAnalysis+1 In the after-hours session, ABBV rose to $223.51, up 0.31%, as of the evening update shown on Investing.com. Investing.com+1 For context, the S&P 500 finished up 0.79% on Thursday,
19 December 2025
····
AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Inc. (NYSE: ABBV) is trading lower on Tuesday, December 16, 2025, after a strong run earlier in the quarter and a Monday close that kept the stock near the upper end of its 52‑week range. As of 17:54 UTC on Dec. 16, ABBV was at $222.44, down $5.01 (-2.20%) on the session, with an intraday range of $222.44 to $228.00. Today’s AbbVie coverage is being driven less by a single blockbuster headline and more by the familiar mix of Wall Street recalibration and pipeline expectations: Bank of America trimmed its price target, while fresh pipeline-focused analysis reiterated the thesis
16 December 2025
·····
AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts

AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts

AbbVie Inc. (NYSE: ABBV) stock traded higher on Monday, December 15, 2025, as investors balanced fresh analyst commentary with new exclusivity-related headlines tied to one of the company’s neuroscience brands. Shares were recently around $227, up roughly 1.7% on the session. For long-term shareholders, the bigger story remains AbbVie’s post-Humira transition: the company is leaning hard on immunology blockbusters Skyrizi and Rinvoq, while also building out oncology and neuroscience pipelines and maintaining an income-focused investor base through a growing dividend. PR Newswire+1 What’s moving AbbVie stock on Dec. 15, 2025 Two headlines stood out in Monday’s flow of AbbVie-related updates:
15 December 2025
·····
1 … 3 4 5 6 7

Stock Market Today

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop